Stay informed
Dropdown menu

Not cancer,

still

destructive

Tenosynovial giant cell tumor (TGCT) is a long-term, noncancerous disease in which tumors form in joints. TGCT is unlikely to spread to other joints but it can cause pain, swelling, and difficulty moving.1,2

If you have pain, swelling, stiffness, or reduced range of motion in any of your joints, ask your doctor about TGCT.1,2

Talking about TGCT 

Doctors may refer to TGCT as “PVNS (pigmented villonodular synovitis)” or “GCT-TS (giant cell tumor of the tendon sheath).”1,3

If these terms come up, remember that they all refer to the same condition: TGCT.

THE CAUSE OF JOINT WRECKAGE1,4

  • 1In TGCT, tumor cells produce too much of a protein called colony stimulating factor 1 or CSF-1
  • 2Too much CSF-1 can cause inflammatory cells to build up in or around a joint
  • 3This can lead to destructive tumor growth, which can cause symptoms like pain, stiffness, and swelling

In TGCT, tumor cells produce too much of a protein called colony stimulating factor 1 or CSF-1

1

Too much CSF-1 can cause inflammatory cells to build up in or around a joint

2

This can lead to destructive tumor growth, which can cause symptoms like pain, stiffness, and swelling

3

2 TYPES OF TGCT

Localized TGCT, also known 
as nodular TGCT5,6

80% to 90% of cases

  • Less aggressive
  • Typically smaller
  • Usually does not spread outside the joint
  • Tends to affect smaller, delicate joints like finger, wrist, or foot joints

Diffuse TGCT5,7

10% to 20% of cases

  • More aggressive
  • Typically larger, can be multiple tumors
  • Can spread outside the joint
  • Tends to affect larger joints like hip, ankle, or knee joints

Both localized and diffuse TGCT2

  • Can be difficult to remove surgically
  • Have a chance of the tumor coming back after TGCT surgery*

*

The chances of the tumor coming back after TGCT surgery are 72% for diffuse TGCT and 34% for localized TGCT, based on a study of nearly 400 people who had surgery.2

THINGS ARE CHANGING IN TGCT

THINGS ARE CHANGING IN TGCT

Sign up now to hear more from us.

STAY INFORMED

REFERENCES

1. Stacchiotti et al. Cancer Treat Rev. 2023;112:1-10. 2. Stern et al. Future Oncol. 2025;21(12):1501-1510. 3. Healey JH, Bernthal NM, van de Sande M. J Am Acad Orth Surg. 2020;4(11):1-17. 4. Hume DA, MacDonald KPA. Blood. 2012;119(8):1810-1820. 5. Gelderblom et al. Cancer. 2021;127:884-893. 6. de Saint Aubain Somerhausen N, van de Rijn M. Tenosynovial giant cell tumor. In: WHO Classification of Tumours of Soft Tissue and Bone. 2020;3:133-136. 7. Righi et al. Clin Sarcoma Res. 2015;5(15):1-4.

YOU ARE NOW LEAVING TGCTWRECKS.COM

By clicking "Continue" below, you will be taken away from tgctwrecks.com to a website that may contain links or references to other websites to which our Privacy Policy may not apply. We encourage you to read the Privacy Policy of every website you visit. You are solely responsible for your interactions with such websites.

CONTINUE TO SITE
RETURN TO TGCTWRECKS.COM
Divider desktop
Divider mobile

©2025 Merck KGaA, Darmstadt, Germany or its affiliates. All rights reserved.

EMD Serono is a Healthcare business of Merck KGaA, Darmstadt, Germany, in the U.S. and Canada.

200 Pier 4 Blvd, Boston, MA 02210

This website is intended only for residents of the United States. Use and access of this site are subject to the terms and conditions set out in our Legal Statement and Privacy Policy.

US-NONOTGCT-00008 11/25